JP2008063316A - アルジトールまたはイノシトール誘導体を骨格とする分子輸送体 - Google Patents
アルジトールまたはイノシトール誘導体を骨格とする分子輸送体 Download PDFInfo
- Publication number
- JP2008063316A JP2008063316A JP2007045647A JP2007045647A JP2008063316A JP 2008063316 A JP2008063316 A JP 2008063316A JP 2007045647 A JP2007045647 A JP 2007045647A JP 2007045647 A JP2007045647 A JP 2007045647A JP 2008063316 A JP2008063316 A JP 2008063316A
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- reaction
- brs
- compound
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000005846 sugar alcohols Chemical class 0.000 title claims abstract description 33
- 229920001223 polyethylene glycol Polymers 0.000 title claims abstract description 25
- 150000004001 inositols Chemical class 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 186
- 239000013543 active substance Substances 0.000 claims abstract description 24
- 239000012528 membrane Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 83
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 38
- 239000000126 substance Substances 0.000 claims description 20
- 229960004679 doxorubicin Drugs 0.000 claims description 18
- 229930012538 Paclitaxel Natural products 0.000 claims description 16
- 229960001592 paclitaxel Drugs 0.000 claims description 16
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 9
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000000600 sorbitol Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 239000012867 bioactive agent Substances 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 abstract description 21
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 abstract description 12
- 230000035699 permeability Effects 0.000 abstract description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 237
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 186
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 132
- 238000006243 chemical reaction Methods 0.000 description 100
- 239000011734 sodium Substances 0.000 description 74
- 238000005160 1H NMR spectroscopy Methods 0.000 description 61
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- 239000007787 solid Substances 0.000 description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- 125000006239 protecting group Chemical group 0.000 description 41
- 229920006395 saturated elastomer Polymers 0.000 description 41
- 238000004440 column chromatography Methods 0.000 description 40
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 38
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 35
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 34
- 238000004519 manufacturing process Methods 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 32
- 239000012044 organic layer Substances 0.000 description 32
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 19
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 18
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 18
- -1 saturated monocyclic hydrocarbon Chemical class 0.000 description 18
- VPWFNCFRPQFWGS-UHFFFAOYSA-N tert-butyl n-[amino-[(2-methylpropan-2-yl)oxycarbonylamino]methylidene]carbamate Chemical group CC(C)(C)OC(=O)NC(N)=NC(=O)OC(C)(C)C VPWFNCFRPQFWGS-UHFFFAOYSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000006260 foam Substances 0.000 description 16
- 239000007789 gas Substances 0.000 description 16
- LQLJNIMZZWZZLE-UHFFFAOYSA-N 4-(iminomethylideneamino)-n,n-dimethylpentan-1-amine;hydrochloride Chemical compound Cl.N=C=NC(C)CCCN(C)C LQLJNIMZZWZZLE-UHFFFAOYSA-N 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 239000012535 impurity Substances 0.000 description 14
- 0 *CN(CCCCCCCCO)CCCN Chemical compound *CN(CCCCCCCCO)CCCN 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 13
- 238000005917 acylation reaction Methods 0.000 description 12
- 229960000367 inositol Drugs 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 125000003277 amino group Chemical group 0.000 description 11
- 210000000170 cell membrane Anatomy 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- 235000014113 dietary fatty acids Nutrition 0.000 description 10
- 229930195729 fatty acid Natural products 0.000 description 10
- 239000000194 fatty acid Substances 0.000 description 10
- 150000004665 fatty acids Chemical class 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical class OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 9
- 229960002920 sorbitol Drugs 0.000 description 9
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 239000012467 final product Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- 239000012948 isocyanate Substances 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 239000008055 phosphate buffer solution Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- VTORJPDWMOIOIQ-UHFFFAOYSA-N tert-butyl(diphenyl)silane Chemical group C=1C=CC=CC=1[SiH](C(C)(C)C)C1=CC=CC=C1 VTORJPDWMOIOIQ-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 5
- 241001085205 Prenanthella exigua Species 0.000 description 5
- 230000010933 acylation Effects 0.000 description 5
- 229960002684 aminocaproic acid Drugs 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 238000002073 fluorescence micrograph Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 4
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 210000000633 nuclear envelope Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- VHOCUJPBKOZGJD-UHFFFAOYSA-N triacontanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O VHOCUJPBKOZGJD-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 150000004579 taxol derivatives Chemical class 0.000 description 3
- KTQKOGBTMNDCFG-UHFFFAOYSA-N tert-butyl(diphenyl)silicon Chemical compound C=1C=CC=CC=1[Si](C(C)(C)C)C1=CC=CC=C1 KTQKOGBTMNDCFG-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical group CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 235000021353 Lignoceric acid Nutrition 0.000 description 2
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 description 2
- FZTLLUYFWAOGGB-UHFFFAOYSA-N 1,4-dioxane dioxane Chemical compound C1COCCO1.C1COCCO1 FZTLLUYFWAOGGB-UHFFFAOYSA-N 0.000 description 1
- LDPFQVWIUACVFE-SVIIGIRWSA-N 2,3:5,6-di-o-isopropylidene-myo-inositol Chemical compound OC1[C@@H]2OC(C)(C)O[C@H]2C(O)[C@H]2OC(C)(C)O[C@H]21 LDPFQVWIUACVFE-SVIIGIRWSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 108700006830 Drosophila Antp Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- DFKCJPSIKCUBFC-UHFFFAOYSA-N NC(=N)N.C(=O)(OC(C)(C)C)NC(SC)=NC(=O)OC(C)(C)C.C(=O)(OC(C)(C)C)NC(SC)=NC(=O)OC(C)(C)C Chemical group NC(=N)N.C(=O)(OC(C)(C)C)NC(SC)=NC(=O)OC(C)(C)C.C(=O)(OC(C)(C)C)NC(SC)=NC(=O)OC(C)(C)C DFKCJPSIKCUBFC-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
- C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
- C07C35/14—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings with more than one hydroxy group bound to the ring
- C07C35/16—Inositols
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
R3は、
R3は、
1)保護された中間体化合物のヒドロキシ基にアシル化(acylation)反応を介してアミノ酸側鎖を導入する段階;
2)段階1)で得た化合物のアミノ酸側鎖の末端アミノ基に、保護されたグアニジン基を導入する段階;および
3)段階2)で得た化合物のグアニジン基の保護基を除去する段階
を含む、前記分子輸送体化合物を製造する方法を提供する。
1)保護された中間体化合物のヒドロキシ基に、アシル化反応を介してアミノ酸側鎖を導入する段階;
2)アミノ酸側鎖末端のアミノ保護基を除去する段階;
3)アミノ酸側鎖末端のアミノ基にグアニジン基を導入する段階;
4)保護されたヒドロキシ基を脱保護した後、生理活性物質とカップリングする段階;および
5)グアニジン基のアミノ保護基を除去する段階
により製造することができる。
MS(FAB)m/z445.22(M++Na)。
MS(FAB) m/z 447.29(M++Na)。
MS(FAB)m/z686.24(M++Na)。
MS(FAB)m/z238.08(M++H)。
MS(FAB)m/z246.15(M++H)。
MS(FAB)m/z514.21(M++H)。
MS(FAB)m/z730.90(M++H)。
MS(FAB)m/z304.18(M++H)。
MS(FAB)m/z382.19(M++Na)。
MS(FAB)m/z650.19(M++Na)
段階4)アミノ基のN,N´−ジ−Boc−グアニジン基への変換
MS(FAB)m/z844.33(M++H)。
MS(FAB)m/z266.10(M++Na)。
(Y.TatiaNa,et al.,J.Am.Chem.Soc.U.S.A.
127:12508,2005)。
MS(MALDI−TOF)m/z2668.40(M++Na)。
5.88(dd,J=14.2Hz,1.9Hz,2H),7.24− 7.68(m,25H)
MS(MALDI−TOF)m/z1593.89(M++Na)。
MS(MALDI−TOF)m/z3533.34(M++Na)。
MS(MALDI−TOF)m/z3987.73(M++Na−2)。
MS(MALDI−TOF)m/z3295.4532(M++Na)。
MS(MALDI−TOF)m/z1950.87(M++Na)。
MS(MALDI−TOF)m/z3750.27(M++Na)。
MS(MALDI−TOF):m/z3997.27(M++Na)。
MALDI−TOF−MS:m/z2407.34(M++Na)。
MS(MALDI−TOF):m/z3867.5923(M++Na+2)。
MS(MALDI−TOF):m/z2020.8277(M++Na+2)。
MS(MALDI−TOF):m/z2372.5631(M++Na)。
.65−7.67(m,4H、芳香族),8.50(brs.,8H),11.48
(brs.,8H)
MS(MALDI−TOF):m/z3292.45(M++Na)。
),11.48(br.s.,8H)
MS(MALDI−TOF)m/z3300.2081(M++Na)。
2−2.38(m,48H),3.02−3.41(m,20H,marged w
ith CD3OD peak at 3.31),3.44−4.19(m,6
H),4.51−4.63(m,4H),5.11−5.36(m,3H),5.68−5.82(m,2H),6.33(br.s.,1H),6.66−6.81(m,6H),7.26−7.73(m,16H),7.98−8.31(m,2H)。
),11.48(br.s.,8H)
MS(MALDI−TOF)m/z2875.4287(M++Na)。
MS(MALDI−TOF):m/z3948.8154(M++Na)。
MALDI−TOF−MS:m/z2088.8975(M++Na)。
MS(MALDI−TOF):m/z4118.0681(M++Na)。
MALDI−TOF−MS:m/z2257.8542(M++Na)。
MALDI−TOF−MS:m/z2342.6512(M++Na)。
MALDI−TOF−MS:m/z2613.0431(M++Na)。
MALDI−TOF−MS:m/z3729.0976(M++Na)。
MALDI−TOF−MS:m/z1884.5143(M++Na)。
MS(FAB)m/z498.22(M++Na)
段階2)イノシトールへのアシル化による側鎖の導入
MS(MALDI−TOF):m/z3346.70(M++Na)。
MS(MALDI−TOF):m/z3555.90(M++Na)。
MS(MALDI−TOF):m/z1933.98(M++Na)。
MS(MALDI−TOF):m/z3555.90(M++Na)。
MS(MALDI−TOF):m/z4012.30(M++Na)。
MS(MALDI−TOF):m/z2409.12(M++Na)。
MS(MALDI−TOF):m/z3402.65(M++Na)。
MS(MALDI−TOF):m/z3657.90(M++Na)。
MS(MALDI−TOF):m/z2056.12(M++Na)。
MS(MALDI−TOF):m/z3858.02(M++Na)。
MS(MALDI−TOF):m/z4113.30(M++Na)。
MS(MALDI−TOF):m/z2512.02(M++Na)。
前記実施例で製造した化合物のNH2基に蛍光物質であるFITC基を選択的にカップリングした後、周知の細胞膜透過性が高いFITC−アルギニン9量体(Fl−Arg9,FITC−Arg9;Peptron)との細胞内および核膜内透過性を比較実験した。
8週齢のC57BL/6マウス(Hyochang Science社製、韓国)に、前記実施例1(81.8mg/kg)、実施例3(95.2mg/kg)、および実施例5(115.6mg/kg)で製造された輸送体化合物を蒸留水に溶かして腹腔注射した。実施例3の化合物の場合、蛍光物質のFITCを別途に導入した。20分後、4%パラホルムアルデヒドPBS(pH7.4)溶液で安楽死させた後、脳を摘出して0.5MスクロースPBS溶液で1日間培養した。低温維持装置を用いて脳を厚さ15μm薄片にし、ガラスのスライドに載せ、37℃で乾燥してからPBSで洗浄し、常温において0.3%TritonX−100で15分間処理して共焦点顕微鏡により分析し、図2に示した。
Claims (7)
- 下記の化1の糖アルコール誘導体またはその塩:
R3は、
- 前記糖アルコール誘導体がソルビトール、マンニトール、またはガラクチトールの立体構造を有するアルジトール誘導体であることを特徴とする、請求項1に記載の糖アルコール誘導体またはその塩。
- 前記塩基性アミノ酸がヒスチジン(histidine)、リシン(lysine)およびアルギニン(arginine)からなる群から選ばれることを特徴とする、請求項1に記載の糖アルコール誘導体またはその塩。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2006-0086106 | 2006-09-07 | ||
KR1020060086106A KR100849033B1 (ko) | 2006-09-07 | 2006-09-07 | 알디톨 또는 이노시톨 유도체를 골격으로 한 분자 수송체 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008063316A true JP2008063316A (ja) | 2008-03-21 |
JP4723526B2 JP4723526B2 (ja) | 2011-07-13 |
Family
ID=39286318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007045647A Expired - Fee Related JP4723526B2 (ja) | 2006-09-07 | 2007-02-26 | アルジトールまたはイノシトール誘導体を骨格とする分子輸送体 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4723526B2 (ja) |
KR (1) | KR100849033B1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008539226A (ja) * | 2005-04-28 | 2008-11-13 | ポステック・ファウンデーション | 糖及びその類似体を骨格とする分子輸送体並びにその製造方法 |
WO2011001657A1 (ja) * | 2009-07-01 | 2011-01-06 | 独立行政法人科学技術振興機構 | ポリイオンデンドリマー、及びそれよりなるハイドロゲル |
JP2011178756A (ja) * | 2010-03-03 | 2011-09-15 | Japan Science & Technology Agency | タンパク質の細胞内導入のためのポリイオンデンドリマー |
JP2011529044A (ja) * | 2008-07-22 | 2011-12-01 | ポステック・アカデミー‐インダストリー・ファウンデーション | イノシトール及びトレハロース誘導体、及びこれを含む退行性脳神経系疾患治療用医薬組成物 |
JP2017519840A (ja) * | 2014-06-27 | 2017-07-20 | ポステック・アカデミー‐インダストリー・ファウンデーションPostech Academy‐Industry Foundation | カチオン性分子輸送体およびアニオン性生物活性材料を含有する皮膚浸透用組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017078467A1 (ko) * | 2015-11-04 | 2017-05-11 | 포항공과대학교 산학협력단 | 양이온성 분자 수송체 및 단백질을 포함하는 피부 투과용 조성물 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005085159A1 (en) * | 2004-03-05 | 2005-09-15 | Postech Foundation | Inositol-based molecular transporters and processes for the preparation thereof |
JP2008539226A (ja) * | 2005-04-28 | 2008-11-13 | ポステック・ファウンデーション | 糖及びその類似体を骨格とする分子輸送体並びにその製造方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834436A (en) * | 1993-04-09 | 1998-11-10 | The Regents Of The University Of California | Membrane-permeant second messengers |
-
2006
- 2006-09-07 KR KR1020060086106A patent/KR100849033B1/ko active IP Right Grant
-
2007
- 2007-02-26 JP JP2007045647A patent/JP4723526B2/ja not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005085159A1 (en) * | 2004-03-05 | 2005-09-15 | Postech Foundation | Inositol-based molecular transporters and processes for the preparation thereof |
JP2008539226A (ja) * | 2005-04-28 | 2008-11-13 | ポステック・ファウンデーション | 糖及びその類似体を骨格とする分子輸送体並びにその製造方法 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008539226A (ja) * | 2005-04-28 | 2008-11-13 | ポステック・ファウンデーション | 糖及びその類似体を骨格とする分子輸送体並びにその製造方法 |
JP2011529044A (ja) * | 2008-07-22 | 2011-12-01 | ポステック・アカデミー‐インダストリー・ファウンデーション | イノシトール及びトレハロース誘導体、及びこれを含む退行性脳神経系疾患治療用医薬組成物 |
US9371350B2 (en) | 2008-07-22 | 2016-06-21 | Postech Foundation | Trehalose derivatives and pharmaceutical compositions for treating neurodegenerative diseases |
WO2011001657A1 (ja) * | 2009-07-01 | 2011-01-06 | 独立行政法人科学技術振興機構 | ポリイオンデンドリマー、及びそれよりなるハイドロゲル |
JP5376543B2 (ja) * | 2009-07-01 | 2013-12-25 | 独立行政法人科学技術振興機構 | ポリイオンデンドリマー、及びそれよりなるハイドロゲル |
US9249275B2 (en) | 2009-07-01 | 2016-02-02 | Japan Science And Technology Agency | Polyionic dendrimer and hydrogel comprising same |
JP2011178756A (ja) * | 2010-03-03 | 2011-09-15 | Japan Science & Technology Agency | タンパク質の細胞内導入のためのポリイオンデンドリマー |
JP2017519840A (ja) * | 2014-06-27 | 2017-07-20 | ポステック・アカデミー‐インダストリー・ファウンデーションPostech Academy‐Industry Foundation | カチオン性分子輸送体およびアニオン性生物活性材料を含有する皮膚浸透用組成物 |
Also Published As
Publication number | Publication date |
---|---|
KR20080022662A (ko) | 2008-03-12 |
JP4723526B2 (ja) | 2011-07-13 |
KR100849033B1 (ko) | 2008-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4955659B2 (ja) | 糖及びその類似体を骨格とする分子輸送体並びにその製造方法 | |
JP4723526B2 (ja) | アルジトールまたはイノシトール誘導体を骨格とする分子輸送体 | |
AU2018205898B2 (en) | Compounds and methods for trans-membrane delivery of molecules | |
IL303504A (en) | GAPMERS OLIGONCLEOTIDE POLY-MORPHOLINO | |
JP2021512082A (ja) | GalNAcオリゴヌクレオチド結合体の調製のための方法 | |
US9463200B2 (en) | Cell-penetrating oligonucleotides | |
KR100578732B1 (ko) | 분자 수송체로서의 이노시톨 유도체 및 이의 제조방법 | |
US7973084B2 (en) | Molecular transporters based on alditol or inositol and processes for the preparation thereof | |
WO2013021355A1 (en) | Functionalized calixarene derivatives for cell transfection | |
DK2079757T3 (en) | Method for selectively placing active substances on and in metochondria and corresponding active substances | |
CN115850358A (zh) | GalNAc簇亚磷酰胺和靶向治疗性核苷 | |
US20230235328A1 (en) | Novel morpholino oligonucleotide derivatives | |
WO2023179773A1 (en) | Bicyclic heterocycles and their ligands for targeted delivery of therapeutic agents | |
US20090036658A1 (en) | Highly efficient synthesis of alpha-O-galactosyl ceramides | |
WO2023176773A1 (ja) | キメラ分子の製造方法 | |
CN117942406A (en) | Use of preformed vectors for the preparation of products for in vitro gene delivery of immune cells and stem cells | |
CN110590877A (zh) | 连接子,载药连接子、细胞穿透肽偶联药物、抗体偶联药物及其制备方法 | |
JP3837633B2 (ja) | 新規な機能性ペプチド核酸およびその製法 | |
Chang et al. | Preparation and Evaluation of BBB-permeable Trehalose Derivatives as Potential Therapeutic Agents for Huntington’s Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100310 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100316 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100614 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100617 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100903 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100910 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100903 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110125 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110308 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110407 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140415 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4723526 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |